This week, Congress passed a bill, the “One Big Beautiful Bill Act,” that will have widespread impacts on the bleeding disorders community – together with millions of others across the country who get health insurance through Medicaid or the Affordable Care Act Marketplaces.

Hemab Therapeutics recently presented clinical and preclinical stage data associated with two of their investigational therapies - Sutacimig (formerly HMB-001) and HMB-002. Hemab is a biotechnology company that specializes in the development of therapies that target underserved bleeding and thrombotic disorders. The data were presented last week at the Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Washington, DC.

Historically, women and girls affected by hemophilia have experienced protracted delays in securing an accurate diagnosis and care that takes bleeding disorders into full account. A newly published paper takes a 200+ year view of this history and provides a better understanding of just how this underserved population has slowly but surely garnered greater visibility and awareness – if not equitable care – over the decades.